Tommaso Stefanelli
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Ruxolitinib in treatment-naive or corticosteroid-refractory pediatric patients with chronic graft-versus-host disease: final analysis of the phase II REACH5 trial.
Journal: Haematologica
Published: October 31, 2025
Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 15, 2025
Role of ruxolitinib in preventing cardiac arrhythmias: A pooled analysis of clinical studies in hematology.
Journal: International journal of cardiology. Heart & vasculature
Published: September 15, 2025
Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 25, 2025
Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study.
Journal: International journal of hematology
Published: February 20, 2024
Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study.
Journal: The Lancet. Haematology
Published: January 30, 2024
A novel approach to visualize clinical benefit of therapies for chronic graft versus host disease (cGvHD): the probability of being in response (PBR) applied to the REACH3 study.
Journal: Bone marrow transplantation
Published: May 17, 2023
A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis.
Journal: HemaSphere
Published: March 14, 2022
A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor.
Journal: BMC cancer
Published: October 04, 2021
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
Journal: The New England journal of medicine
Published: July 14, 2021
A 5-year follow-up to evaluate the efficacy and safety of ofatumumab added to fludarabine and cyclophosphamide in patients with relapsed chronic lymphocytic leukemia: final analysis of the COMPLEMENT 2 trial.
Journal: Leukemia & lymphoma
Published: February 29, 2020
Five-year survival follow-up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukaemia: a short report.
Journal: British journal of haematology
Published: September 06, 2019
Last Updated: 09/26/2026